Privately held Aragon Pharmaceuticals Inc. landed $42 million in an oversubscribed Series C financing to advance its pipeline of therapies targeting hormone-driven cancers, including ARN-509, the company's lead compound for the treatment of castration-resistant prostate cancer (CRPC).
Regenerative medicine pioneer Aastrom Biosciences Inc. enrolled the first patient in its Phase III REVIVE trial assessing the efficacy and safety of ixmyelocel-T in critical limb ischemia (CLI). The primary endpoint of the trial will be amputation-free survival at 12 months.
Privately held Concert Pharmaceuticals Inc. increased its bandwidth by signing an exclusive licensing agreement with Avanir Pharmaceuticals Inc. for the global rights to develop and commercialize multiple deuterium-modified dextromethorphan (d-DM) compounds developed by Concert for neurological and psychiatric disorders, as well as certain rights to additional unspecified d-DM compounds.
Privately held Angiochem Inc. signed a global collaboration with GlaxoSmithKline plc potentially worth more than C$300 million (US$300.3 million) to discover, develop and commercialize treatments for lysosomal storage diseases (LSDs).
One of the oldest conditions known to humans, epilepsy continues to confound drug developers, with nearly one in three patients refractory on one or more antiepileptic drugs.
Privately held Satori Pharmaceuticals Inc. raised $15 million in an inside round from existing investors as it prepares to move its Alzheimer's disease (AD) technology into the clinic.
Privately held Collegium Pharmaceutical Inc. closed a $22.5 million Series B round to advance its development program for COL-003, a tamper-resistant, extended-release oxycodone product that uses its DETERx technology.
Threshold Pharmaceuticals Inc. saw shares rocket as high as 88 percent Tuesday morning after the company reported its Phase IIb study evaluating TH-302 in advanced pancreatic cancer hit its primary endpoint.
Boosted by 2011 net revenues of $210.5 million in the U.S., including fourth-quarter net revenues of $57.2 million, thanks to sales of Ampyra (dalfampridine) extended-release tablets, Acorda Therapeutics Inc. said Thursday it inked a deal to acquire privately held Neuronex Inc., which is developing a nasal spray formulation of diazepam for certain epilepsy patients.
Mnemosyne Pharmaceuticals Inc., an emerging biotech targeting central nervous system (CNS) disorders, raised $5.4 million in a Series A financing to advance its work on a class of molecules known as subunit selective NMDA receptor modulators (SNRMs).
